EBITDA clocked Rs 1,185 crore and EBITDA margin stood 24 per cent for Q3FY21.
Dr. Reddy’s Laboratories on Friday posted December third quarter consolidated web revenue at Rs 20 crore in contrast with a lack of Rs 569.7 crore within the year-ago interval.
The corporate mentioned the Q3FY21 revenue after tax (PAT) was affected majorly because of the non-recognition of deferred tax belongings on impairment.
Income for the mentioned quarter got here at Rs 4,930 crore that was up 12 per cent year-over-year and 1 per cent quarter-over-quarter.
Gross margin stood at 53.8 per cent in contrast with 54.1 per cent year-over-year and 53.9 per cent quarter-over-quarter.
Promoting, common and administrative bills (SGNA) bills rose 14 per cent year-over-year and 10 per cent quarter-over-quarter to Rs 1,439 crore. Analysis and Improvement (R&D) bills stood at Rs 411 crore for the quarter.
Earnings earlier than curiosity, taxes, depreciation, and amortisation (EBITDA) clocked Rs 1,185 crore and EBITDA margin stood 24 per cent for Q3FY21.
Dr Reddy’s mentioned on Monday an unbiased board discovered Russia’s Sputnik V Covid-19 vaccine to be protected in its mid-stage trial in India, and really useful progressing to late-stage trials.
The corporate has submitted the mid-stage trial security information to India’s drug regulator for overview and approval to proceed late-stage trials, Dr Reddy’s mentioned in a regulatory submitting.
